Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Conditions:   Any Solid Tumors;   Mesothelioma;   Head and Neck Squamous Cell Carcinoma;   Ovarian Cancer;   Hepatocellular Carcinoma;   Squamous Cell Carcinoma of Lung;   Esophageal Cancer;   Adenoid Cystic Carcinoma;   Prostate Cancer;   Cervical Cancer;   Gastric Cancer;   Melanoma;   Acute Myeloid Leukemia;   Non Hodgkin Lymphoma;   Thymic Carcinoma and Thymoma;   Progressor of PD-1/PD-L1 Immunotherapy
Intervention:   Drug: VMD-928 300 mg Tablet (ongoing); 100 mg Capsule (complete)
Sponsor:   VM Oncology, LLC
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

April 15, 2022Comments OffClinicalTrials.gov | Gastroenterology Clinical Trials | Gastroenterology Studies | US National Library of Medicine
Comments